C4 Therapeutics, Inc. (CCCC) Total liabilities 2021–2025
C4 Therapeutics, Inc. (CCCC) total liabilities at each fiscal year-end, per SEC filings.
$102.5MFY2025 · since FY2021: $117.2M → $102.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $102.5M | -23.3% |
| FY2024 | $133.6M | +2.5% |
| FY2023 | $130.3M | -8.0% |
| FY2022 | $141.6M | +20.9% |
| FY2021 | $117.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More CCCC financial trends
CCCC RevenueCCCC Net incomeCCCC Net marginCCCC Gross profitCCCC Gross marginCCCC Operating incomeCCCC Operating marginCCCC Operating cash flowCCCC Free cash flowCCCC Capital expendituresCCCC Return on equityCCCC Stock buybacksCCCC Dividends paidCCCC Total assetsCCCC Shareholders’ equityCCCC overview →